检索结果-南通市图书馆

Novel Non-Protein Biomarkers for Early Detection of Hepatocellular Carcinoma

Engineering 2021年第10期7卷 1369-1374页

作者： ghassan k.abou-alfa Lin Wu Augusto Villanueva Memorial Sloan kettering Cancer Center New York CityNY 10065USA Weill Medical College Cornell UniversityNew York CityNY 10065USA Berry Oncology Corporation Beijing 102200China Division of Liver Diseases Division of Hematology/Medical OncologyLiver Cancer ProgramDepartment of MedicineTisch Cancer InstituteIcahn School of Medicine at Mount SinaiNew York CityNY 10029USA

Early detection of hepatocellular carcinoma(HCC)while in its early stages is critical for reducing HCC mortality in high-risk ***,highly sensitive and specific surveillance biomarkers for early-stage HCC detection are still *** recent years,great efforts have been made to research tumor-derived molecular features that are detectable in circulation,such as circulating tumor deoxyribonucleic acid and circulating tumor ribonucleic acid,in order to explore their potential as noninvasive biomarker candidates in many tumor *** this review,we summarize current studies on these new approaches and their application in early HCC detection.

关键词： Hepatocellular carcinoma Early detection Biomarkers Liquid biopsy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Liver-directed therapiesfor fibrolamellar carcinoma:Asingle-center experience

引用

Oncology Research 2024年第12期32卷 1831-1836页

作者： SAM SON AkSHAAR BRAHMBHATT kEN ZHAO BRETT MARINELLI JAMES HARDING WILLIAM JARNAGIN ghassan k.abou-alfa HOOMAN YARMOHAMMADI Department of Radiology Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA Department of Medicine Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA Division of Hepatobiliary Surgery Department of SurgeryMemorial Sloan Kettering Cancer Center and Weill Medical College at Cornell UniversityNew YorkNY 10065USA

Background:This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma(FLC)treated with liver-directed therapies(LDT).Methods:In this single-center retrospective study,all patients diagnosed with FLC who underwent LDT were identiﬁ*** July 2012 and July 2023,six patients were identiﬁ*** patient was excluded due to *** and clinical parameters were *** within 30 days of the LDT were *** treatment responses at 1,6,and 12 months were assessed per ***:A total ofﬁve patients,which included three females and two males,were *** patients were treated with transarterial hepatic embolization(TAE;n=3),transarterial radioembolization(TARE;n=1),and combined TAE+radiofrequency ablation(n=1).The objective response rate at one month was 80%[CR=2(40%),PR=2(40%),and SD=1(20%)].At 12 months(n=4),two patients demonstrated CR(50%)and two demonstrated PR(50%).Overall survival from LDT atﬁve years was 50%.There was no 30-day mortality among this group of patients or any adverse event attributable to the ***:TAE,TARE,and ablation are safe and effective therapeutic options for *** on this study and previously published case reports,ablation and TARE yielded the most favorable results.

关键词： Fibrolamellar carcinoma(FLC) Hepatocellular carcinoma(HCC) Liver-directed therapy(LDT) Transarterial radioembolization(TARE) Hepatic artery embolization

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current status and future of systemic therapy for hepatocellular carcinoma

引用

Cancer Biology & Medicine 2018年第S1期15卷 25-25页

作者： ghassan abou-alfa Memorial Sloan kettering Cancer Center New YorkUSA

Hepatocellular carcinoma(HCC)has been perceived as a malignancy that is resistant to systemic chemotherapy for long periods of *** initial efforts that were supported by the NCI to help elucidate any potential role for systemic doxorubicin,no standard of care was approved and acknowledged for HCC until the advent of ***,a multi-kinase inhibitor with an anti-angiogenic effect,was evaluated in a large phase III clinical trial versus placebo and showed a clear improvement of survival in its favor,which helped establish it as a standard of *** was back in 2007,and since then we lingered in a long hiatus of several genuine attempts to test potentially more powerful anti-angiogenics to no *** 2017,things changed markedly with 4 clinical trials showing improvements in survival or non-inferiority *** the first line setting,lenvatinib,another multi-kinase inhibitor with anti-angiogenic and anti-FGF activity showed non-inferiority versus sorafenib and is now FDA *** the second line setting,*** multikinase inhibitor with ample similarity to sorafenib but some differences showed improvement in survival after progression on sorafenib when tested against ***,another multi-kinase inhibitor with anti-c-met activity also showed an improvement in survival versus placebo,while ramicirumab also showed an improvement in survival versus placebo in the same setting yet only for patients with elevated alpha fetoprotein(AFP).The advent of checkpoint inhibitors has already led to the approval of anti-PD-1 nivolumab in the second line setting based on a response rate of 15%-20%despite the lack of survival *** studies are now evaluating the combination of different checkpoint inhibitors and also the combination of checkpoint inhibitors plus multikinase *** incredible increase in the number of targeted therapies and checkpoint inhibitors from 1 to 6 cannot go unnoticed,adding to the already

关键词： Current status future systemic

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：